Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10® and Keytruda® for First-Line Stage III Melanoma at Melanoma Bridge 2022
December 01, 2022 07:00 ET
|
Provectus Biopharmaceuticals Inc.
50% CR and 83% ORR by RECIST 1.1 criteriaRapid CRs achieved within 15 to 27 weeksMedian PFS not reached during 2-year treatment interval; 83% PFS rate100% OS rate for CRs; ongoing after 18 to 36...
Provectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022
November 10, 2022 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company’s ongoing, multi-cohort, Phase 1b/2 study of the combination therapy of cancer...
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2021 Congress
September 27, 2021 06:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from historical clinical trials and expanded access studies of investigational cancer...